Knowledge Boost: The Latest Clinical Evidence on MEK Inhibition in Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Knowledge Boost: The Latest Clinical Evidence on MEK Inhibition in Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Are you familiar with MEK inhibitors and their role in treating neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PNs)? Are you up to date with relevant clinical trial data on MEK inhibition in NF1 PNs released within the year? Through this interactive Booster Quiz, test your knowledge, competency, and confidence in the latest data on new and emerging MEK inhibitors for NF1-associated PNs. This unique learning experience provides: instant expert feedback on your answer selections opportunity to see how well you do relative to your peers downloadable summary with key supporting evidence and relevant practice tips.

  • Provider:PRIME Education, Inc. (PRIME®)
  • Activity Link: https://primeinc.org/online/accelerating-adoption-latest-clinical-evidence-into-clinical-practice-nf1
  • Start Date: 2024-09-11 05:00:00
  • End Date: 2024-09-11 05:00:00
  • Credit Details: AAPA Category 1 Credit™️: 0.25 hours
    AMA PRA Category 1 Credit™️: 0.25 hours
    Nursing: 0.25 hours
    Pharmacy: 0.25 hours
  • Commercial Support: Source: Springworks Therapeutics - Amount: 24875.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner/Team Competence, Learner/Team Performance
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.